Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

NCT ID: NCT03671330

Last Updated: 2025-10-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 327 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-08-29
• Study Completion Date: 2025-05-09

Brief Summary

This is a Phase II randomized, double-blind, placebo-controlled study involving premenopausal and postmenopausal Chinese women plus an open-label single arm of pharmacokinetic cohort of LEE011 in combination with Letrozole in Chinese postmenopausal women with HR+, HER2- negative advanced breast cancer.

Three cohorts of patients will be enrolled: PK cohort, premenopausal cohort, and postmenopausal cohort.

Conditions

Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Ribociclib

Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.

Premenopausal experimental arm: NSAI + Goserelin + Ribociclib; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.

It is the investigators choice for NSAI based on patient's past medical history.

Postmenopausal experimental arm:

Letrozole + Ribociclib

PK Cohort: Open-label ribociclib + Letrozole treatment combination.

For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent

Group Type: EXPERIMENTAL

Ribociclib

Intervention Type: DRUG

Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.

NSAI: Letrozole or Anastrazole

Intervention Type: DRUG

Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).

Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.

For postmenopausal and PK cohorts, all patients will be on Letrozole.

Letrozole

Intervention Type: DRUG

Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).

Ribociclib Placebo

Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.

Premenopausal control arm: NSAI + Goserelin + Placebo; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.

It is the investigators choice for NSAI based on patient's past medical history.

Postmenopausal control arm:

Letrozole + Placebo For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent

Group Type: PLACEBO_COMPARATOR

Ribociclib Placebo

Intervention Type: DRUG

Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.

Ribociclib

Intervention Type: DRUG

Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.

NSAI: Letrozole or Anastrazole

Intervention Type: DRUG

Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).

Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.

For postmenopausal and PK cohorts, all patients will be on Letrozole.

Letrozole

Intervention Type: DRUG

Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).

Goserelin

Intervention Type: DRUG

Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle

Interventions

Ribociclib Placebo

Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.

Intervention Type: DRUG

Ribociclib

Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.

Intervention Type: DRUG

NSAI: Letrozole or Anastrazole

Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).

Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.

For postmenopausal and PK cohorts, all patients will be on Letrozole.

Intervention Type: DRUG

Letrozole

Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).

Intervention Type: DRUG

Goserelin

Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle

Intervention Type: DRUG

Other Intervention Names

LEE011 Placebo; LEE011

Eligibility Criteria

Inclusion Criteria

• Patient has a histologically and/or cytologically confirmed diagnosis of estrogen receptor (ER) positive and/or progesterone receptor positive breast cancer by local laboratory (based on most recently analyzed biopsy).
• Patient has HER2-negative breast cancer (based on most recently analyzed biopsy) defined as a negative in situ hybridization test or an Immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing.
• Patient must have either:

• Measurable disease, i.e., at least 1 measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (a lesion at a previously irradiated site may only be counted as a target lesion if there is a clear sign of progression since the irradiation). OR
• If no measurable disease is present, then at least 1 predominantly lytic bone lesion must be present (patients with no measurable disease and only 1 predominantly lytic bone lesion that has been previously irradiated are eligible if there is documented evidence of disease progression of the bone lesion after irradiation).
• Patient has ECOG performance status 0 or 1.

For premenopausal cohort:

• Patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent and has signed informed consent before any trial related activities are conducted and according to local guidelines.
• Confirmed negative serum pregnancy test before starting study treatment or patient has had a hysterectomy.
• Patient has advanced (loco regionally recurrent not amenable to curative therapy or metastatic) breast cancer not amenable to curative therapy (e.g.

surgery and/or radiotherapy).

• Patients who received ≤ 14 days of a NSAI (letrozole or anastrozole) with or without goserelin or goserelin ≤ 28 days for advanced breast cancer prior to randomization are eligible. Patients must continue treatment with the same hormonal agent + goserelin during the study. No treatment interruption is required for these patients prior to randomization.
• Patients who have received up to 1 line of chemotherapy for advanced breast cancer and have been discontinued 28 days before randomization are eligible.

For postmenopausal cohort:

• Patient is an adult, female ≥ 18 years old at the time of informed consent and has signed informed consent before any trial related activities and according to local guidelines.
• Women with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.

Exclusion Criteria

• Patient who has received a prior CDK4/6 inhibitor.
• Patient with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgment
• Patient with CNS metastases.
• Patient who has not had resolution of clinical and laboratory acute toxicities related to prior anti-cancer therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 Grade ≤1.
• Patient has a known history of Human immunodeficiency Virus (HIV) infection (testing not mandatory).
• Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
• Patient is currently receiving any of the substances as defined in the protocol that cannot be discontinued 7 days prior to the start of the treatment:

For premenopausal cohort:

• Pregnant or nursing (lactating) women.
• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of study treatment and for 21 days after stopping study medication.

Note: Use of oral (estrogen and progesterone), transdermal, injected or implanted hormonal methods of contraception as well as hormonal replacement therapy is not allowed in this study.

For postmenopausal cohort:

• Patient who received any prior systemic anti-cancer therapy (including hormonal therapy and chemotherapy) for advanced breast cancer.

Note: Patients who received neo (adjuvant) therapy for breast cancer are eligible. If the prior neo (adjuvant) therapy included letrozole or anastrozole, the disease free interval must be greater than 12 months from the completion of treatment until randomization.

• Patients who received ≤ 14 days of letrozole or anastrozole for advanced disease prior to randomization are eligible.

Other protocol-defined inclusion/exclusion may apply.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Novartis Investigative Site

Hefei, Anhui, China

Novartis Investigative Site

Beijing, Beijing Municipality, China

Novartis Investigative Site

Chongqing, Chongqing Municipality, China

Novartis Investigative Site

Guangzhou, Guangdong, China

Novartis Investigative Site

Shijiazhuang, Hebei, China

Novartis Investigative Site

Harbin, Heilongjiang, China

Novartis Investigative Site

Changsha, Hunan, China

Novartis Investigative Site

Nanjing, Jiangsu, China

Novartis Investigative Site

Suzhou, Jiangsu, China

Novartis Investigative Site

Nanchang, Jiangxi, China

Novartis Investigative Site

Changchun, Jilin, China

Novartis Investigative Site

Shengyang, Liaoning, China

Novartis Investigative Site

Shengyang, Liaoning, China

Novartis Investigative Site

Xian, Shanxi, China

Novartis Investigative Site

Chengdu, Sichuan, China

Novartis Investigative Site

Kunming, Yunnan, China

Novartis Investigative Site

Hangzhou, Zhejiang, China

Novartis Investigative Site

Hangzhou, Zhejiang, China

Novartis Investigative Site

Beijing, , China

Novartis Investigative Site

Fuzhou, , China

Novartis Investigative Site

Qingdao, , China

Novartis Investigative Site

Shanghai, , China

Novartis Investigative Site

Shanghai, , China

Novartis Investigative Site

Tianjin, , China

Countries

China

Other Identifiers

CLEE011A2206

Identifier Type: -

Identifier Source: org_study_id